Atherosclerotic Cardiovascular Risk With Combination Avelumab and Axitinib

J Clin Oncol. 2022 Oct 10;40(29):3467-3469. doi: 10.1200/JCO.22.00712. Epub 2022 Jun 16.

Authors

Sean Tan¹, Daphne Day¹, Stephen J Nicholls¹, Eva Segelov¹

Affiliation

¹ Sean Tan, MBBS, Victorian Heart Institute, Monash University, Melbourne, Australia, Monash Heart, Monash Health, Clayton, Victoria, Australia; Daphne Day, MBBS, School of Clinical Sciences, Monash Health, Monash University, Melbourne, Australia, Department of Oncology, Monash Health, Clayton, Victoria, Australia; Stephen J. Nicholls, MBBS, PhD, Victorian Heart Institute, Monash University, Melbourne, Australia, Monash Heart, Monash Health, Clayton, Victoria, Australia; and Eva Segelov, MBBS, PhD, School of Clinical Sciences, Monash Health, Monash University, Melbourne, Australia, Department of Oncology, Monash Health, Clayton, Victoria, Australia.

PMID: 35709408
DOI: 10.1200/JCO.22.00712

No abstract available

Publication types

Letter
Research Support, Non-U.S. Gov't
Comment

MeSH terms

Antibodies, Monoclonal, Humanized
Axitinib / adverse effects
Carcinoma, Renal Cell*
Cardiovascular Diseases* / chemically induced
Heart Disease Risk Factors
Humans
Kidney Neoplasms*
Risk Factors

Substances

Antibodies, Monoclonal, Humanized
Axitinib
avelumab